Tue, Sep 16, 2014, 10:15 AM EDT - U.S. Markets close in 5 hrs 45 mins

Recent

% | $
Quotes you view appear here for quick access.

Boston Scientific Corporation Message Board

  • bandit_sam_jewel bandit_sam_jewel Dec 26, 1997 10:39 AM Flag

    Bard Receives Approval For TELESCOPE cat

    Bard Receives Approval For The Revolutionary New TELESCOPE Angioplasty Catheter

    MURRAY HILL, NJ--(BUSINESS WIRE)--December 23, 1997--C.R. Bard, Inc. (NYSE-BCR) today announced it has received U.S. Food and Drug Administration clearance to market the revolutionary new TELESCOPE(TM) Single Operator over-the-wire balloon catheter.

    The TELESCOPE balloon catheter is the first fully interchangeable, single operator angioplasty device to combine over-the-wire performance with a standard length guidewire. This technologically superior TELESCOPE catheter revolutionizes PTCA catheter shaft design by providing the interventional cardiologist with a totally new level of flexibility and versatility.

    As its name suggests, the unique shaft of the TELESCOPE catheter is constructed from telescoping segments, allowing the
    physician to swiftly and easily shorten or lengthen the catheter according to the requirements of the procedure. In addition, the
    TELESCOPE catheter offers a patented anti-backbleed and wirelock system which minimizes blood loss during the PTCA procedure. The
    TELESCOPE catheter also features Bard's unique patented Rely(R) balloon material which is widely recognized for its superior
    performance during difficult multi-lesion cases.

    ``Since our pioneering work in balloon angioplasty in the 1970s, our research engineers have continually strived to provide the interventional cardiologist with new and innovative devices to treat coronary artery disease. Now they have reached a new level of achievement with the TELESCOPE catheter system,'' commented William H. Longfield, Bard's chairman and chief executive officer.

    ``This unique catheter provides not only flexibility and ease of use, but also the potential to substantially reduce the
    balloons required and cost per procedure.'' Bard plans to launch the TELESCOPE catheter in the U.S. market in early 1998, where
    several patents currently limit the cardiologists' choice in single operator systems. Bard will continue to supply its markets
    outside the U.S. with its latest generations of over-the-wire and rapid exchange catheters. The TELESCOPE will eventually be
    launched worldwide when production volumes permit.

    ANy comments as the the potential impact of this catheter. Is this a novel new approach? Will it meet any unmet needs? How will it be received?

 
BSX
12.29-0.10(-0.81%)10:15 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.